Hafrun Fridriksdottir - Feb 28, 2022 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role
Executive VP, Global R&D
Signature
/s/ Dov Bergwerk as attorney-in-fact for Hafrun Fridriksdottir
Stock symbol
TEVA
Transactions as of
Feb 28, 2022
Transactions value $
-$61,799
Form type
4
Date filed
3/2/2022, 06:47 AM
Previous filing
Feb 10, 2022
Next filing
Mar 8, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TEVA Ordinary Shares Options Exercise +21.7K +42.17% 73.1K Feb 28, 2022 Direct F1, F2
transaction TEVA Ordinary Shares Sale -$61.8K -7.59K -10.38% $8.14 65.5K Feb 28, 2022 Direct F1, F3, F4, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TEVA Restricted Share Units Options Exercise $0 -21.7K -33.33% $0.00 43.4K Feb 28, 2022 Ordinary Shares 21.7K Direct F1, F2, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3 The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F4 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.035 to $8.255, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
F6 Restricted share units were granted on February 28, 2020, with 21,682 having vested on each of February 28, 2021 and February 28, 2022, 21,682 vesting on February 28, 2023 and 21,684 vesting on February 28, 2024.